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Abstract 
Background: Several studies show that anesthesia for primary cancer surgery might influence cancer recurrence regulating spe-
cific gene expression like the Neuroepithelial Transforming (NET) 1 protein. This gene has been associated with malignant behav-
iors and represents a novel prognostic marker in human epithelial cancers. The present study investigates the in vitro effects of a 
clinically available propofol formulation on NET1 expression in canine mammary tumor cells, as a potential translational model.
Methods: Two canine mammary tumor cell lines, primary (CIPp) and metastatic (CIPm), were incubated with propofol (1-10 μg 
ml-1). Cells were lysate and RNA isolated at pre-established time points. A quantitative PCR was performed to evaluate NET1 gene 
expression and resulting delta cycle thresholds compared. 
Results: Baseline NET1 gene expression was lower in CIPm compared with CIPp. Both propofol concentrations increased NET1 
mRNA levels in CIPp after 6 hours. In CIPm the higher propofol concentration caused a reduction in gene expression after 6 hours. 
Propofol decreased gene expression in both cell lines and only in CIPp after 12 and 24 hours, respectively. No differences were 
found in CIPm after 48 hours. The higher concentration of propofol increased gene expression in CIPp after 48 hours.
Conclusions: Metastatic cells showed a lower basal NET1 expression and were less responsive to treatments compared to primary 
tumor cells. Propofol effectively influenced NET1 gene expression without a clear dose dependency. Most treatment time-points 
showed a decreased NET1 gene expression, although increases were also observed.
DOI:10.29011/AVST-136/100036
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Introduction
All around the world, breast cancer represents the most wide-
ly diffuse type of cancer in women. It is also reported as the second 
most frequent cause of cancer related death, usually as a result of 
metastatic spread [1]. Surgical removal of the primary tumor is 
considered to be the most effective treatment for patients diag-
nosed with malignant breast cancer [2]. However, recent studies 
suggest that some anesthetic techniques may facilitate or impede 
cancer spread via different mechanisms [3]. In particular, the intra-
venous anesthetic agent propofol may have anti-cancer properties 
by promoting apoptosis in some cancer cell lines [4], initiating the 
activation of T-helper cells and promoting the differentiation of 
T-helper 1 cells [5] among some described mechanisms.
In this context, interest is raising towards the effects of drugs 
on the expression of genes that are associated with tumor cell mi-
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gration like the Neuroepithelial Cell Transforming (NET) 1 gene. 
The NET1 gene, a RhoA specific Guanine Nucleotide Exchange 
Factor (GEF), has a fundamental role in the organization of actin 
filaments in the cytoskeleton and its overexpression may increase 
the ability of breast adenocarcinoma cells to migrate and invade 
[6]. In vitro studies have shown that NET1 gene expression in hu-
man tumor cells can be influenced by drugs used in the periopera-
tive period. In particular, in a study from Ecimovic and colleagues 
(2014), it was shown that cells cultured under propofol exposure 
significantly decreased NET1 gene expression reducing cells mi-
gration, a phenomenon, the latter, which was reversed after NET1 
gene silencing [7].
In recent years, canine tumors have been postulated as trans-
lational models of naturally occurring cancer in people [8]. Based 
on the fact that dogs have shorter life spam and consequently that 
canine tumors require shorter time to metastasize, clinical canine 
patients affected with mammary tumors could be adopted as a nat-
ural model for the study of mammary tumor progression in a faster 
fashion. However, to the author’s knowledge, there are no studies 
evaluating the influence of anesthetics on the expression of NET1 
gene in canine mammary tumor cells. Based on this, the aim of the 
present study is to evaluate NET1 gene expression and the effects 
of two concentrations of a clinically available Propofol formula-
tion on such expression in primary (CIPp) and metastatic (CIPm) 
canine mammary tumor cell lines.
Methods
Cell Culture
Primary canine tubular adenocarcinoma’s cells (CIPp) and 
metastatic canine tubular adenocarcinoma’s cells (CIPm) derived 
from the same patient were used for this study [9]. Both cell lines 
were cultivated in Roswell Park Memorial Institute (RPMI) me-
dium supplemented with 10% fetal bovine serum, 100 μg ml-1 pe-
nicillin, 100 μg ml-1 streptomycin, 1.5 mg ml-1 amphotericin B and 
incubated for 24 hours at 37°C in a humidified atmosphere with 5% 
CO2 (Sigma-Aldrich, Italy).
Drug Exposure
Cells were seeded in triplicates onto p6 culture plates (Ep-
pendorf, Italy) and treated with 1 and 10 µg ml-1 (P1 and P10 tre-
atments, respectively) of Vetofol® (Esteve SpA, Italy) a clinically 
available propofol formulation, for 6, 12, 24 and 48 hours. Cells 
cultured without anesthetics were used as baseline. 
Total RNA Extraction
Total RNA was isolated using the Trizol Reagent (Thermo 
Fisher Scientific, Italy) according to the manufacturer`s instruction. 
In short, after removing the growth medium and washing the cells 
with PBS, Trizol Reagent was added to 80% confluent cell cultu-
res. After a 5-minute incubation period, cell lysates were transfer-
red into a 1.5 ml microfuge tube and 200 μl of chloroform were 
added. Thereafter, the samples were incubated at room temperatu-
re (25°C) for 15 minutes followed by centrifugation at 13,000 × g 
at 4°C for other 15 minutes. The upper aqueous layer containing 
RNA was transferred into a 1.5 ml tube. Ice-cold isopropanol (0.5 
ml) was added to the aqueous phase, the tube was shaken and left 
to stand on ice for 10 minutes before it was centrifuged at 13,000 
× g at 4°C for 10 minutes. The supernatant was removed and the 
pellet was washed with 1 ml 75% ethanol. After centrifugation at 
7,500 × g for 5 minutes, ethanol was removed and the pellet was 
allowed to air-dry for 5 minutes. Pellets were re-suspended in 50 
μl of nuclease-free water and incubated at 60°C for 15 minutes. 
RNA was stored at -80°C.
Complementary DNA (cDNA) synthesis
Total RNA was quantified using the Experion Electrophore-
sis System (Bio-Rad, Italy). cDNA was synthesized from 1 µg of 
total RNA using a quantiscript reverse transcriptase test (Quanti-
Tect Reverse Transcription kit; Qiagen, Italy) as follows: 1 µg of 
total RNA was subjected to DNAse treatment using 2 μl of gDNA 
Wipeout Buffer in a total reaction volume of 14 μl. Samples were 
incubated at 42°C for 2 minutes and chilled on ice for 10 minutes. 
Then 1 μl of Quantiscript Reverse Transcriptase, 4 μl of Quantis-
cript RT Buffer 5X and 1 μl of RT Primer mix were added. The 
samples were subsequently incubated for 15 minutes at 42°C follo-
wing 3 minutes at 95°C to inactivate Quantiscript Reverse Trans-
criptase.
Quantitative PCR expression by real time PCR
To determine the relative amounts of specific NET1 gene 
transcript, 1 μl of cDNA was used for quantitative PCR using 
the IQ SYBR Green Super mix (Bio-Rad, Italy) and the IQ5 
detection system (Bio-Rad, Italy). The sequences of primers 
used for PCR were: canine glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; GenBank entry: AB038240.1) forward 5′-
GGCACAGTCAAGGCTGAGAAC-3′, canine GAPDH reverse 
5′-CCAGCATCACCCCATTTGAT-3′, canine NET1 (GenBank 
entry: XM_54427.5) forward 5’-CATCAAGAGGACGATCCG-
GG-3’, canine NET1 reverse 5’-ATTGCTTGGCTCCTCTTG-
CT-3’. The reaction conditions were as follows: reverse transcrip-
tion: 95°C for 3 minutes (1 cycle) followed by denaturation at 95°C 
for 30 seconds and annealing at 60°C for 30 seconds (35 cycles). 
Data analysis using the delta cycle threshold (ΔΔCt) method was 
performed using an optical system software (IQ5, Bio-Rad, Ita-
ly). The GAPDH expression levels were used to normalize NET1 
expression. The level of gene expression was calculated using a 
relative quantification assay corresponding to the comparative Ct 
method: the amount of target, normalized to the endogenous ho-
usekeeping gene (GAPDH) and relative to the calibrator (control 
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sample), was then transformed by 2ΔΔCt (fold increase), where 
ΔΔCt = ΔCt (sample)-ΔCt (control) and ΔCt is the Ct of the target 
gene subtracted from the Ct of the housekeeping gene. To perform 
statistical analysis, ΔCts were compared using a 3-way ANOVA 
test (cell, treatment, time) or a student t-test as relevant. Signifi-
cance was set at p < 0.05.
Results 
In the present study expression of NET1 gene was detected 
in both primary and metastatic cell lines cultured without Propofol 
in the sole culture medium with a statistically significant higher 
expression in CIPp compared to CIPm (median ΔCt 5.82 and 6.48 
respectively; p = 0.000375). Mean ΔCts values over time for CIPp 
and CIPm are presented in Table 1 and Table 2, respectively.
Table 1: Neuroepithelial Transforming (NET) 1 gene expression reported 
as mean delta cycle threshold (ΔCt) values in the primary canine tubular 
adenocarcinoma’s cells (CIPp) after 12-24-48 hours of P1 (A; 1 µg ml-1) 
or P10 (B; 10 µg ml-1) exposures.
Table 2: Neuroepithelial Transforming (NET) 1 gene expression reported 
as mean delta cycle threshold (ΔCt) values in the metastatic canine tubular 
adenocarcinoma’s cells (CIPm) after 12-24-48 hours of P1 (A; 1 µg ml-1) 
or P10 (B; 10 µg ml-1) exposures.
After 6 hours of exposure, CIPp cells treated with both con-
centrations of Vetofol® showed significantly higher NET1 gene 
expression than controls (Figure 1). 
Figure 1: Overtime fold changes in Neuroepithelial Transforming (NET) 
1 gene expression vs. Baseline under P1 (A; 1 µg ml-1) and P10 (B; 10 
µg ml-1) exposures in the primary canine tubular adenocarcinoma’s cells 
(CIPp; * = p < 0.05, *** = p < 0.005). 
In CIPm, a statistically significant difference was found be-
tween controls and the higher concentration of Vetofol®, the latter 
showing lower gene expression (Figure 2). 
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nificant reduction in NET1 gene expression compared to controls.
After 48 hours of exposure, no differences were found be-
tween controls and treatments in CIPm. Conversely, in CIPp the 
higher concentration of Vetofol® induced a significant increase in 
gene expression.
Discussion
This is the first study focused on the biological effect of a 
clinically available propofol formulation on NET1 gene expres-
sion in canine mammary cell lines. Both, P1 and P10 induced a 
decreased NET1 gene expression in CIPp after 12 and 24 hours of 
exposure while only the higher concentration (i.e. P10) caused a 
reduction of NET1 gene expression in CIPm after 6 and 12 hours 
of exposure. Paradoxically, an increased NET1 gene expression 
was observed in CIPp with both Vetofol® concentrations and with 
the higher Vetofol® concentration after 6 and 48 hours of exposu-
re, respectively. To the authors’ knowledge, this is the first time 
that such a divergent effect has been described for a clinically ava-
ilable propofol formulation in a primary canine tumor cell line. 
Unfortunately, the reasons why these divergent effects were ob-
served cannot be explained with the current study. As previous-
ly described, the NET1 gene is critical for Transforming Growth 
Factor (TGF) 1-induced cytoskeletal reorganization, N-cadherin 
expression, and RhoA activation [10]. As a RhoA specific GEF it 
plays an important role in the Epithelial-Mesenchymal Transition 
(EMT), enabling tumor cells to invade and migrate [11]. Silencing 
of this gene has been associated with abrogation of the inhibitory 
effect of propofol on cancer cells migrating ability [7]. Therefore, 
a reduction in NET1 gene expression may be interpreted as a po-
tentially anti-metastatic effect. On the other hand, an increase of 
NET1 gene expression could be interpreted as an increase in the 
ability of the tumor cells to cause metastasis [12]. Consistently, the 
co-expression of NET1 gene and α6β4 integrin in the primary tu-
mors of node-positive patients with invasive breast carcinoma was 
associated with decreased distant metastasis-free survival [6].
Cell lines originating from the same individual, but with dif-
ferent malignant potentials, were chosen to compare the effects 
of propofol on primary and metastatic cells. NET1 mRNA was 
detectable in both CIPp and CIPm; however, NET1 gene showed 
a higher expression in CIPp compared to CIPm. These results may 
suggest that CIPp have a higher invasiveness potential than CIPm. 
Indeed, it has been speculated that intrinsic mechanisms promo-
ting cell invasion and migration would be enhanced in CIPp since 
this cell line is responsible for the dissemination of the tumor to 
remote locations within the body [9]. On the other hand, mecha-
nisms responsible for cell migration may be attenuated in CIPm in 
order for these cells to be able to adhere to each other and grow, 
establishing metastatic lesions in distant organs. 
Figure 2: Overtime fold changes in Neuroepithelial Transforming (NET) 
1 gene expression vs. Baseline under P1 (A; 1 µg ml-1) and P10 (B; 10 µg 
ml-1) exposures in the metastatic canine tubular adenocarcinoma’s cells 
(CIPm; * = p < 0.05).
After 12 hours of exposure, NET1 mRNA levels were signifi-
cantly decreased with both concentrations of Vetofol® in CIPp and 
the lower concentration of Vetofol® in CIPm compared to controls. 
After 24 hours of exposure, no differences were found in 
CIPm, while in CIPp both concentrations of Vetofol® induced a sig-
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The doses of Propofol reported in the present study were 
chosen because they reflect the clinically achieved plasma concen-
trations obtained during Propofol anesthesia and sedation in dogs 
[13]. Interestingly, a generic chemical form of Propofol at con-
centrations like the ones reported here (i.e. between 1 and 10 µg 
ml-1) reduced NET1 gene expression by 49-79% in MDA-MB-231 
cells, an estrogen-receptor-negative human breast adenocarcinoma 
cell line and by 42-88% in MCF7 cells, an estrogen and progeste-
rone-receptor-positive human breast adenocarcinoma cell line [7]. 
Different to the present study in which the NET1 expression was 
reduced on CIPm only with the high concentration of Vetofol®, the 
authors reported a lack of dose-effect in MDA-MB-231 cells and 
MCF7 cells. However, this is comparable to the results obtained 
from CIPp in which both doses of Vetofol® influenced NET1 gene 
expression and a dose-effect could not be demonstrated. 
In the present study different results were found at different 
time-points; however, the observed time-effects did not follow a 
linear pattern. Interestingly, with the shortest exposure time (i.e. 6 
hours), an increase of NET1 mRNA levels in CIPp was observed. 
This finding was surprising and seems to speak for an enhance-
ment of malignancy in primary tumor cells when exposed to Veto-
fol® for that period of time. However, this effect was reversed after 
12 and 24 hours of exposure, where Vetofol® induced a decrease 
in gene expression in CIPp. Thereafter, a significant increase in 
NET1 gene expression was observed once again in that cell line. 
This observation could suggest that there is a time-dependent re-
sponse in the expression of NET1 gene of CIPp when exposed to 
Vetofol®. Some sort of time dependency was already noticed after 
observing that NET1 expression tended to return to the baseline in 
MDA-MB-231 cells and MCF7 cells after 4 hours of incubation 
with lysophosphatidic acid [7]. On the other hand, the only signifi-
cant changes observed in CIPm were the reduction in NET1 gene 
expression. Unfortunately, the present study does not provide eno-
ugh elements for a comprehensive explanation of the phenomenon.
It is unclear how Propofol modulates the expression of 
NET1 gene. In a previous study it was suggested that Propofol mo-
dulates NET1 by changing the cellular microenvironment, rather 
than by a specific receptor pathway [7]. Other studies underline the 
relationship between TGF-β, microRNAs and NET1 expression 
as combined targets for Propofol anti-metastatic activity [14-17], 
with, for instance, TGF-β increasing NET1 and mediating stress 
fiber formation in human keratinocytes [16]. The potential anti-
cancer properties of Propofol have been previously reported in se-
veral studies. For instance, Propofol induces cancer cell apoptosis 
in human promyelocytic leukemia HL-60 [18] and hepatic cancer 
cells HepG2 [19]. In pancreatic cancer cells (i.e. MIA-PaCa-2) 
Propofol promoted apoptosis in a dose-dependent manner (20). 
Propofol inhibited invasion, angiogenesis and induced apoptosis 
of human esophageal squamous Cell Carcinoma (i.e. EC-1) cells 
in vitro through regulation of S100A4 expression [21]. In addition, 
propofol suppressed the epithelial-mesenchymal transition and 
consequently kidney fibrosis through TGF-β/Smad 3 signaling and 
regulating miR-155 levels [18] and decreased cancer cell invasion 
via nuclear NF-kb pathway inhibition and subsequent reduction of 
matrix metalloproteinase 2 and matrix metallopeptidase 9 levels in 
human MDA-MB-231 cells [19]. Mammoto and colleagues sho-
wed that sub-anesthetic propofol infusions for 4 weeks effectively 
inhibited pulmonary metastasis in mice inoculated with murine 
osteosarcoma cells and suggested its possible anti-invasive action 
in vivo [22]. 
Paradoxically, propofol has also been associated with me-
chanisms that may promote cancer. Propofol induced proliferation 
and promoted invasion of gallbladder cancer cells through acti-
vation of Nrf2, in a dose- and time- dependent manner [23]. In 
another study, human breast cancer cells (i.e. MDA-MB-468) mi-
grated in a higher proportion and at a faster velocity than controls 
in a dose-dependent manner when exposed to propofols [24].
There were some limitations to the current study. The gene 
expression of NET1 was investigated in canine mammary tumor 
cells without performing biological tests. Although it can be sta-
ted that Vetofol® effectively influenced the expression of a gene 
closely related with increased cancer cells malignancy, the con-
clusions cannot be extended to the effects on cellular behavior. In 
particular, it would be interesting to verify in the future whether 
the expression of NET1 gene is correlated with increased migra-
tion potential in canine mammary tumor cells and if the decreased 
NET1 gene expression caused by propofol effectively decreases 
(or increases) cell migration. In addition, it would be expected that 
silencing NET1 gene in the presence of propofol would return the 
migration parameters to those obtained at baseline. Finally, the use 
of a clinically available propofol formulation cannot ensure that 
the changes observed in the present study are solely related to the 
active compound, propofol. In addition to propofol, the emulsion 
contains soybean oil (100 mg/mL), glycerol (22.5 mg/mL), egg 
lecithin (12 mg/mL) and disodium edetate (0.005%), with sodium 
hydroxide to adjust pH. The role of the adjuvants in the expression 
of NET1 gene would need further clarification. 
Conclusions
The reported propofol formulation effectively modified ca-
nine mammary cancer cells NET1 gene expression. Both the con-
centrations examined in the present study induced a decrease in 
gene expression in the most treatment time-points, although incre-
ases in gene expression were also observed. Further studies, in-
cluding biological tests and gene silencing are warranted to better 
understand this phenomenon.
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